Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

Nanoliposome targeting in breast cancer is influenced by the tumor microenvironment.

Dumont N, Merrigan S, Turpin J, Lavoie C, Papavasiliou V, Geretti E, Espelin CW, Luus L, Kamoun WS, Ghasemi O, Sahagian GG, Muller WJ, Hendriks BS, Wickham TJ, Drummond DC.

Nanomedicine. 2019 Apr;17:71-81. doi: 10.1016/j.nano.2018.12.010. Epub 2019 Jan 14.

PMID:
30654182
2.

Safety and pharmacokinetics of MM-302, a HER2-targeted antibody-liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study.

Munster P, Krop IE, LoRusso P, Ma C, Siegel BA, Shields AF, Molnár I, Wickham TJ, Reynolds J, Campbell K, Hendriks BS, Adiwijaya BS, Geretti E, Moyo V, Miller KD.

Br J Cancer. 2018 Oct;119(9):1086-1093. doi: 10.1038/s41416-018-0235-2. Epub 2018 Oct 26.

3.

64Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer.

Lee H, Shields AF, Siegel BA, Miller KD, Krop I, Ma CX, LoRusso PM, Munster PN, Campbell K, Gaddy DF, Leonard SC, Geretti E, Blocker SJ, Kirpotin DB, Moyo V, Wickham TJ, Hendriks BS.

Clin Cancer Res. 2017 Aug 1;23(15):4190-4202. doi: 10.1158/1078-0432.CCR-16-3193. Epub 2017 Mar 15.

4.

Inflammation and Lymphedema Are Exacerbated and Prolonged by Neuropilin 2 Deficiency.

Mucka P, Levonyak N, Geretti E, Zwaans BMM, Li X, Adini I, Klagsbrun M, Adam RM, Bielenberg DR.

Am J Pathol. 2016 Nov;186(11):2803-2812. doi: 10.1016/j.ajpath.2016.07.022. Epub 2016 Oct 14.

5.

Dual HER2 Targeting with Trastuzumab and Liposomal-Encapsulated Doxorubicin (MM-302) Demonstrates Synergistic Antitumor Activity in Breast and Gastric Cancer.

Espelin CW, Leonard SC, Geretti E, Wickham TJ, Hendriks BS.

Cancer Res. 2016 Mar 15;76(6):1517-27. doi: 10.1158/0008-5472.CAN-15-1518. Epub 2016 Jan 12.

6.

VEGF-A/NRP1 stimulates GIPC1 and Syx complex formation to promote RhoA activation and proliferation in skin cancer cells.

Yoshida A, Shimizu A, Asano H, Kadonosono T, Kondoh SK, Geretti E, Mammoto A, Klagsbrun M, Seo MK.

Biol Open. 2015 Jul 24;4(9):1063-76. doi: 10.1242/bio.010918.

7.

Cyclophosphamide-Mediated Tumor Priming for Enhanced Delivery and Antitumor Activity of HER2-Targeted Liposomal Doxorubicin (MM-302).

Geretti E, Leonard SC, Dumont N, Lee H, Zheng J, De Souza R, Gaddy DF, Espelin CW, Jaffray DA, Moyo V, Nielsen UB, Wickham TJ, Hendriks BS.

Mol Cancer Ther. 2015 Sep;14(9):2060-71. doi: 10.1158/1535-7163.MCT-15-0314. Epub 2015 Jul 10.

8.

A gradient-loadable (64)Cu-chelator for quantifying tumor deposition kinetics of nanoliposomal therapeutics by positron emission tomography.

Lee H, Zheng J, Gaddy D, Orcutt KD, Leonard S, Geretti E, Hesterman J, Harwell C, Hoppin J, Jaffray DA, Wickham T, Hendriks BS, Kirpotin D.

Nanomedicine. 2015 Jan;11(1):155-65. doi: 10.1016/j.nano.2014.08.011. Epub 2014 Sep 6.

PMID:
25200610
9.

Single-cell quantitative HER2 measurement identifies heterogeneity and distinct subgroups within traditionally defined HER2-positive patients.

Onsum MD, Geretti E, Paragas V, Kudla AJ, Moulis SP, Luus L, Wickham TJ, McDonagh CF, MacBeath G, Hendriks BS.

Am J Pathol. 2013 Nov;183(5):1446-1460. doi: 10.1016/j.ajpath.2013.07.015. Epub 2013 Sep 11.

PMID:
24035511
10.

Designing CXCL8-based decoy proteins with strong anti-inflammatory activity in vivo.

Falsone A, Wabitsch V, Geretti E, Potzinger H, Gerlza T, Robinson J, Adage T, Teixeira MM, Kungl AJ.

Biosci Rep. 2013 Sep 17;33(5). pii: e00068. doi: 10.1042/BSR20130069.

11.

HER2-targeted liposomal doxorubicin displays enhanced anti-tumorigenic effects without associated cardiotoxicity.

Reynolds JG, Geretti E, Hendriks BS, Lee H, Leonard SC, Klinz SG, Noble CO, Lücker PB, Zandstra PW, Drummond DC, Olivier KJ Jr, Nielsen UB, Niyikiza C, Agresta SV, Wickham TJ.

Toxicol Appl Pharmacol. 2012 Jul 1;262(1):1-10. doi: 10.1016/j.taap.2012.04.008. Epub 2012 Apr 21.

PMID:
22676972
12.

Multiscale kinetic modeling of liposomal Doxorubicin delivery quantifies the role of tumor and drug-specific parameters in local delivery to tumors.

Hendriks BS, Reynolds JG, Klinz SG, Geretti E, Lee H, Leonard SC, Gaddy DF, Espelin CW, Nielsen UB, Wickham TJ.

CPT Pharmacometrics Syst Pharmacol. 2012 Nov 21;1:e15. doi: 10.1038/psp.2012.16.

13.

A mutated soluble neuropilin-2 B domain antagonizes vascular endothelial growth factor bioactivity and inhibits tumor progression.

Geretti E, van Meeteren LA, Shimizu A, Dudley AC, Claesson-Welsh L, Klagsbrun M.

Mol Cancer Res. 2010 Aug;8(8):1063-73. doi: 10.1158/1541-7786.MCR-10-0157. Epub 2010 Jul 22.

14.

Novel svVEGF isoforms from Macrovipera lebetina venom interact with neuropilins.

Aloui Z, Hoos S, Geretti E, Kharmachi H, Haumont PY, Mejdoub H, Klagsbrun M, England P, Gasmi A.

Biochem Biophys Res Commun. 2009 Nov 6;389(1):10-5. doi: 10.1016/j.bbrc.2009.08.068. Epub 2009 Aug 18.

PMID:
19695228
15.

A biophysical insight into the RANTES-glycosaminoglycan interaction.

Rek A, Brandner B, Geretti E, Kungl AJ.

Biochim Biophys Acta. 2009 Apr;1794(4):577-82. doi: 10.1016/j.bbapap.2009.01.001.

PMID:
19455751
16.

Neuropilin structure governs VEGF and semaphorin binding and regulates angiogenesis.

Geretti E, Shimizu A, Klagsbrun M.

Angiogenesis. 2008;11(1):31-9. doi: 10.1007/s10456-008-9097-1. Epub 2008 Feb 19. Review.

PMID:
18283547
17.

Site-directed mutagenesis in the B-neuropilin-2 domain selectively enhances its affinity to VEGF165, but not to semaphorin 3F.

Geretti E, Shimizu A, Kurschat P, Klagsbrun M.

J Biol Chem. 2007 Aug 31;282(35):25698-707. Epub 2007 Jun 26.

18.

Neuropilins: novel targets for anti-angiogenesis therapies.

Geretti E, Klagsbrun M.

Cell Adh Migr. 2007 Apr-Jun;1(2):56-61. Epub 2007 Apr 25. Review.

19.

Developing chemokine mutants with improved proteoglycan affinity and knocked-out GPCR activity as anti-inflammatory recombinant drugs.

Potzinger H, Geretti E, Brandner B, Wabitsch V, Piccinini AM, Rek A, Kungl AJ.

Biochem Soc Trans. 2006 Jun;34(Pt 3):435-7. Review.

PMID:
16709180
20.

Identification of the glycosaminoglycan binding site of the CC chemokine, MCP-1: implications for structure and function in vivo.

Lau EK, Paavola CD, Johnson Z, Gaudry JP, Geretti E, Borlat F, Kungl AJ, Proudfoot AE, Handel TM.

J Biol Chem. 2004 May 21;279(21):22294-305. Epub 2004 Mar 18.

21.

A structural and dynamic model for the interaction of interleukin-8 and glycosaminoglycans: support from isothermal fluorescence titrations.

Krieger E, Geretti E, Brandner B, Goger B, Wells TN, Kungl AJ.

Proteins. 2004 Mar 1;54(4):768-75.

PMID:
14997572

Supplemental Content

Loading ...
Support Center